GLPwatch

GLPwatch (visit www.glpwatch.org) is a daily-updated public database that tracks GLP-1 drugs and the molecules behind them. It pulls together official data — drug labels, clinical trials, research papers, and adverse-event reports — so anyone can look up evidence-based information on medications like Ozempic, Wegovy, Mounjaro, and Zepbound in one place.

What is GLPwatch?

GLP-1 receptor agonists have become some of the most-discussed medications in the world, but reliable information about them is scattered across regulatory filings, trial registries, scientific journals, and safety databases. GLPwatch answers a simple need: a single, neutral reference that aggregates those official sources rather than promotional material.

You can explore the full database at glpwatch.org, where GLPwatch's GLP-1 drug tracker covers 13 branded drugs and 15 molecules — including semaglutide, tirzepatide, and retatrutide — alongside thousands of clinical trials, research papers, and safety reports.

What GLPwatch tracks

GLPwatch organises GLP-1 information across several dedicated areas, refreshed daily from public records:

Each day the database detects and logs changes, with a changelog in the News section so readers can see what was updated and when.

Who GLPwatch is for

GLPwatch is built for anyone who wants evidence-based information on GLP-1 medications drawn from official sources — patients researching a prescription, clinicians comparing options, researchers tracking the literature, and analysts following the pipeline and the manufacturers behind it.

Who built GLPwatch

GLPwatch is a project by Blackfinch, a Warsaw-based mobile and web consultancy. It sits alongside our other data-driven tools — including FlutterTrends, a daily leaderboard of the top 20,000 packages on pub.dev — that turn large public datasets into clear, daily-updated references.

Explore the database at glpwatch.org.